Tigecycline is being investigated by Stem Cell Therapeutics for its use in the treatment of acute myeloid leukaemia (AML), a type of cancer that affects a patient's blood and bone marrow. There were just under 15,000 new cases of the disease reported in the US in 2013 and more than 10,000 deaths. Read the full story